Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01455948
Other study ID # JJMC-001
Secondary ID
Status Terminated
Phase Phase 4
First received October 11, 2011
Last updated September 1, 2015
Start date February 2012
Est. completion date November 2012

Study information

Verified date September 2015
Source Johnson & Johnson Medical Companies
Contact n/a
Is FDA regulated No
Health authority Canada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

The economic, patient related outcome, and effectiveness of balloon sinuplasty in the treatment of CRS patients with frontal and other sinus disease in the Canadian healthcare environment is not known at this time. This study will evaluate the impact of balloon sinuplasty and traditional FESS treatment on CRS patients.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date November 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Documented diagnosis of unilateral or bilateral Chronic Rhinosinusitis based on the European Position Paper on Rhinosinusitis and Nasal Polyps (2) with at least frontal and maxillary sinus involvement

- Documented failed medical treatment of CRS

- Eighteen (18) to sixty-five (65) years of age

- Employed in full time position or equivalent

- Planned FESS for treatment of CRS

- Must have an American Society of Anesthesiologists physical status of P3 classification or less

- Able to provide informed consent by signing the informed consent document at the screening visit prior to any study activities

- Able to read and understand English

Exclusion Criteria:

- Previous sinonasal surgery

- Pregnant

- Cystic Fibrosis

- Diagnosed immotile cilia syndrome

- Samter's Triad

- Diagnosed immunodeficiency syndrome

- Diagnosed fungal sinusitis

- Concurrent septoplasty or turbinate surgery

- Diagnosed recurrent acute sinusitis

- Current smoker

- Presence of grade 2 or greater nasal polyps

- Sinonasal tumors or obstructive lesions

- History of substance or alcohol abuse within the past 12 months

- Investigator's opinion that the subject should not be in the study such as any conditions that could compromise the wellbeing of the patient or integrity of the study or prevent the patient from meeting or performing study requirements

- Participation in a research study 30 days prior to surgery

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Device:
Relieva Balloon Sinuplasty™ System
Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
Procedure:
Functional Endoscopic Sinus Surgery
Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.

Locations

Country Name City State
Canada Hamilton General Hospital Hamilton Ontario
Canada St. Joseph's Health Centre London Ontario
Canada Ottawa Hospital - Civic Campus Ottawa Ontario
Canada Mount Sinai Hospital Toronto Ontario
Canada St. Joseph's Health Centre Toronto Ontario
Canada St. Michael's Hospital Toronto Ontario
Canada Toronto East General Toronto Ontario
Canada Trillium Health Centre Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Johnson & Johnson Medical Companies Acclarent

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary The direct and indirect costs of treatment of frontal and other sinus disease with Functional Endoscopic Sinus Surgery or balloon sinuplasty. 6 months No
Secondary Health outcome of patients in the two treatment groups. Health outcomes will be determined by the completion of the EQ-5D questionnaire in both treatment groups at various timepoint. The EQ-5D is a standardised measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. Applicable to a wide range of health conditions and treatments, it provides a simple descriptive profile and a single index value for health status that can be used in the clinical and economic evaluation of health care as well as in population health surveys. 6 months No
Secondary Effectiveness of the two treatment groups in relieving symptomology of CRS. Effectiveness of the two treatment groups in relieving symptomology of CRS will be determined by the completion of the Sino-nasal Outcome Test - 20 (SNOT-20) questionnaire in both treatment groups at various timepoint. The SNOT-20 questionnaire is a validated instrument for the measurement of disease specific health status and quality of life in patients with chronic rhinosinusitis. 6 months No
See also
  Status Clinical Trial Phase
Completed NCT04131686 - NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Completed NCT02692794 - Large Scale Cerebral Oximetry During Sinus Endoscopy N/A
Completed NCT01988779 - Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations Phase 3
Completed NCT01254916 - The Sinonasal Outcome Test - 22, Validated for Danish Patients N/A
Completed NCT03614923 - Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Phase 2
Completed NCT03781804 - Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps Phase 3
Completed NCT01198912 - Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial Phase 2
Active, not recruiting NCT06457100 - Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Surgery Phase 1/Phase 2
Completed NCT03280537 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Phase 3
Terminated NCT02285283 - Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps Phase 2/Phase 3
Completed NCT02307825 - Azithromycin for Patients With Chronic Rhinosinusitis Failing Medical and Surgical Therapy Phase 4
Completed NCT02218307 - The Use of Antibiotic Sinonasal Rinse After Sinus Surgery Phase 4
Recruiting NCT01024075 - Effect of Sinufoam-Dexamethasone Mixture on Post Endoscopic Sinus Surgery Outcomes Phase 4
Completed NCT01002313 - Effect of Prednisone onTregs and TH17 Phase 1
Completed NCT00396162 - Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis Phase 4
Completed NCT03280550 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Phase 3
Recruiting NCT05935683 - Rhinosinusitis Italian Network: the Italian Registry for Severe, Uncontrolled Chronic Rhinosinusitis
Completed NCT03478930 - An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Phase 3
Completed NCT01943370 - Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement N/A
Completed NCT02154555 - A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery N/A